SEC Form 10-K filed by Olema Pharmaceuticals Inc.
$OLMA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2024 | $24.00 | Buy | Goldman |
| 1/30/2024 | $20.00 | Buy | Citigroup |
| 7/21/2023 | $21.00 | Outperform | Oppenheimer |
| 5/5/2023 | $16.00 | Overweight | CapitalOne |
| 2/22/2023 | $12.00 | Outperform | Credit Suisse |
| 7/6/2022 | $16.00 | Buy | Canaccord Genuity |
| 6/9/2022 | $12.00 | Neutral → Buy | H.C. Wainwright |
| 2/28/2022 | Neutral | HC Wainwright & Co. |
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w
SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)